SARS-CoV-2 antibodies detectable up to seven months post COVID-19 onset, shows new Portuguese study

October 23, 2020

A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) with an interdisciplinary team of clinicians and researchers from Faculdade de Medicina da Universidade de Lisboa (FMUL) and Centro Hospitalar Lisboa Norte (CHLN) and collaborators at Instituto Português do Sangue e Transplantação (IPST), shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19. These results, now published in the scientific journal European Journal of Immunology, also show that age is not a confounding factor in levels of antibodies produced, but disease severity is.

This comprehensive and cross-sectional study was thought off in the early days of the pandemic, back in March 2020. The researchers Patrícia Figueiredo-Campos and Birte Blankenhaus, first authors of this study, setup an in-house sensitive specific and versatile COVID-19 serology test. The optimization and validation of the assay was performed as part of Serology4COVID, a consortium of 5 research institutes of Lisbon and Oeiras. Collaborating with physicians in the campus of the Santa Maria Hospital, the research team started to monitor the antibody levels of over 300 COVID-19 hospital patients and healthcare workers, and over 200 post-COVID-19 volunteers.

"Our immune system recognizes the virus SARS-CoV-2 as harmful and produces antibodies in response to it, which helps to fight the virus." "The results of this 6 months cross-sectional study show a classic pattern with a rapid increase of antibody levels within the first three weeks after COVID-19 symptoms and, as expected, a reduction to intermediate levels thereafter", explains Marc Veldhoen, adding that "in this early response phase, on average men produce more antibodies than women, but levels equilibrate during the resolution phase and are similar between the sexes in the months after SARS-CoV-2 infection". In the acute phase of the immune response, the team observed higher antibody levels in subjects with more severe disease. Also, the results show that age is not a confounding factor for the production of antibodies, as no significant differences were observed between age groups. Globally, 90% of subjects have detectable antibodies up to 7 months post contracting COVID-19.

Next, the research team, evaluated the function of these antibodies, i.e. their neutralizing activity against the virus SARS-CoV-2. In collaboration with Instituto Português do Sangue e Transplantação (IPST), the research team analysed the neutralizing capacity of the antibodies produced by the patients and volunteers. "Although we observed a reduction in the levels of antibodies over time, the results of our neutralizing assays have shown a robust neutralisation activity for up to the seventh month post-infection in a large proportion of previously virus-positive screened subjects", explains Marc Veldhoen.

On the importance of this study, Marc Veldhoen states: "Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2. The next months will be critical to evaluate the robustness of the immune response to SARS-CoV-2 infection, and to find clues for some open questions, such as the duration of circulating antibodies and the impact of reinfection."
This study was conducted at iMM in collaboration with the Biobank-IMM, Lisbon Academic Medical Centre, Faculdade de Medicina da Universidade de Lisboa (FMUL), Centro Hospitalar Lisboa Norte (CHLN) and Instituto Português do Sangue e Transplantação (IPST). The SARS-CoV-2 protein used in the serology testing was produced at Instituto de Biologia Experimental e Tecnológica (iBET) as part of the Serology4COVID consortium. This work was funded by the European Union H2020 ERA project EXCELLtoINNOV (No 667824), the Fundação para a Ciência a Tecnologia and Sociedade Francisco Manuel dos Santos.

Instituto de Medicina Molecular

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to